OncRef

Clinical Trial: NCT02747004

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Eli Lilly and Company
Information Provided By:Eli Lilly and Company
Last Update Posted:2026-10-16

Study Overview

Brief Summary

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer.

Official Title

A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer

Conditions

Metastatic Breast Cancer

Intervention / Treatment

  • Drug: Abemaciclib
  • Drug: Tamoxifen
  • Drug: Prophylactic Loperamide

Other Study ID Numbers

  • 16339
  • I3Y-MC-JPCG
  • 2016-000288-18
  • 2016

Start Date (Actual)

2016-09-14

Primary Completion Date (Actual)

2018-06-15

Study Completion Date (Actual)

2026-09-09

Enrollment (Actual)

234

Study Type

Interventional

Phase

Phase 2